The U.S. Food and Drug Administration has approved GSK's prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles (herpes zoster). The ...
Among older adults who received at least one dose of the recombinant shingles vaccine, vaccine effectiveness against any herpes zoster-related outcome was 56.1%. Getting a second dose yielded a ...
Older adults vaccinated against shingles have lower dementia risk, a new study says. Shingles vaccination linked to lower dementia risk, more evidence suggests. Image credit: Luis Velasco/Getty Images ...
Researchers estimate that during their lifetime, one out of every three people will develop shingles — a viral condition causing an extremely painful rash that eventually blisters. Since 2006, older ...
Hosted on MSN
Shingles vaccination rates rose during the COVID-19 pandemic, but major gaps remain for underserved groups
Vaccination against shingles increased among adults age 50 and older in the U.S. during the COVID-19 pandemic, but not equally across all population groups. That’s the key finding from a new study my ...
Uptake of the recombinant zoster vaccine (RZV) among adults with rheumatic diseases in the 20 months following the updated 2021 recommendations ranged from 7% to just more than 10% across conditions.
Please provide your email address to receive an email when new articles are posted on . Researchers evaluated patients with HIV and herpes zoster for adverse events by vaccination status. They found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results